Publication: Immunohistochemical study of cyclin A and p16 expression in patients with renal cell carcinoma
dc.contributor.author | Latic, Dragana (57201659994) | |
dc.contributor.author | Radojevic-Skodric, Sanja (15726145200) | |
dc.contributor.author | Nikolic, Srdjan (56427656200) | |
dc.contributor.author | Prvanovic, Mirjana (57201654195) | |
dc.contributor.author | Lazic, Miodrag (35929198300) | |
dc.contributor.author | Dzamic, Zoran (6506981365) | |
dc.contributor.author | Bogdanovic, Ljiljana (24167847400) | |
dc.contributor.author | Radunovic, Milena (56490840800) | |
dc.contributor.author | Vukovic, Marina (57213381743) | |
dc.date.accessioned | 2025-07-02T12:17:48Z | |
dc.date.available | 2025-07-02T12:17:48Z | |
dc.date.issued | 2017 | |
dc.description.abstract | Purpose: Renal cell carcinoma (RCC) is the most common malignant kidney tumor in adults. Dysregulation of the cell cycle can lead to cancer development. In this study, the mitosis-associated cyclin A and p16, a negative controller, were investigated as potential key points in the RCC development. Methods: This retrospective study included 74 patients with RCC. The expression of cyclin A and p16 and their correlation to histopathological parameters (TNM stage, histological subtype, nuclear grade, tumor size), gender, age, and clinical outcome were studied and analyzed. Results: The highest median value for cyclin A (40%; range 0-70)) and for p16 (57.5%; range 35-80) were found in the papillary histological subtype. Survival analysis showed that in the group of patients that had died before September 2015, the median value for cyclin A was 20% (range 0-60), which was significantly higher than 5% (range 0-70), found in the group of patients that survived (p=0.019). Conclusions: In relation to the histological subtype, the papillary type of RCC was associated with a significantly higher expression of cyclin A and p16 compared to other subtypes of RCC. High expression of cyclin A indicated worse prognosis, therefore cyclin A could be considered to be a significant prognostic marker. © 2017 Zerbinis Publications. All rights reserved. | |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85045537362&partnerID=40&md5=1c8c41ef8ba886069a08a6fbbae33eb1 | |
dc.identifier.uri | https://remedy.med.bg.ac.rs/handle/123456789/13096 | |
dc.subject | Cyclin A | |
dc.subject | Immunohistochemistry | |
dc.subject | P16 | |
dc.subject | Renal cell carcinoma | |
dc.title | Immunohistochemical study of cyclin A and p16 expression in patients with renal cell carcinoma | |
dspace.entity.type | Publication |